NuVasive Inc. (NASDAQ:NUVA) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $65.00 and last traded at $64.75, with a volume of 215,326 shares traded. The stock had previously closed at $63.51.

Several research analysts recently issued reports on the stock. Brean Capital increased their price target on shares of NuVasive from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Morgan Stanley reiterated a “hold” rating and issued a $57.00 price target on shares of NuVasive in a research note on Tuesday, June 7th. Jefferies Group reiterated a “buy” rating on shares of NuVasive in a research note on Wednesday, August 3rd. Cowen and Company reiterated a “buy” rating and issued a $63.00 price target (up from $52.00) on shares of NuVasive in a research note on Wednesday, April 27th. Finally, Zacks Investment Research lowered shares of NuVasive from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 27th. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $64.38.

The firm has a market cap of $3.24 billion and a P/E ratio of 66.90. The stock has a 50-day moving average price of $62.03 and a 200-day moving average price of $53.20.

NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Tuesday, July 26th. The medical device company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm earned $236.50 million during the quarter, compared to the consensus estimate of $232.86 million. During the same quarter in the previous year, the firm earned $0.31 earnings per share. The business’s revenue was up 16.4% compared to the same quarter last year. On average, analysts expect that NuVasive Inc. will post $1.65 EPS for the current year.

In related news, Director Lesley H. Howe sold 3,602 shares of NuVasive stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $62.44, for a total value of $224,908.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jason Hannon sold 14,534 shares of NuVasive stock in a transaction dated Thursday, June 16th. The shares were sold at an average price of $57.57, for a total value of $836,722.38. Following the completion of the sale, the executive vice president now owns 37,616 shares of the company’s stock, valued at $2,165,553.12. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in NUVA. RS Investment Management Co. LLC increased its position in shares of NuVasive by 403.7% in the fourth quarter. RS Investment Management Co. LLC now owns 753,190 shares of the medical device company’s stock worth $40,755,000 after buying an additional 603,650 shares in the last quarter. Nicholas Co. Inc. WI increased its position in shares of NuVasive by 45.0% in the fourth quarter. Nicholas Co. Inc. WI now owns 61,960 shares of the medical device company’s stock worth $3,352,000 after buying an additional 19,240 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of NuVasive by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,030,568 shares of the medical device company’s stock worth $55,765,000 after buying an additional 32,254 shares in the last quarter. Jennison Associates LLC increased its position in shares of NuVasive by 41.5% in the fourth quarter. Jennison Associates LLC now owns 412,893 shares of the medical device company’s stock worth $22,342,000 after buying an additional 121,061 shares in the last quarter. Finally, Redwood Investments LLC increased its position in shares of NuVasive by 94.6% in the fourth quarter. Redwood Investments LLC now owns 26,431 shares of the medical device company’s stock worth $1,430,000 after buying an additional 12,851 shares in the last quarter.

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.